Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 6/20 | 0.63 |
| ▸ | VEGFA | P15692 | 2/20 | 0.53 |
| ▸ | AKT1 | P31749 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6929410 | 1.00 | SELP (0.63) | SELPVEGFAAKT1ALDH1A1LMNA | |
| SCHEMBL6925912 | 0.92 | VEGFA (0.64) | SELPVEGFAALDH1A1LMNATLR2 | |
| SCHEMBL6927239 | 0.92 | VEGFA (0.64) | SELPVEGFAALDH1A1LMNATLR2 | |
| SCHEMBL6831894 | 0.92 | VEGFA (0.64) | SELPVEGFAALDH1A1LMNATLR2 | |
| SCHEMBL6838278 | 0.92 | VEGFA (0.64) | SELPVEGFAALDH1A1LMNATLR2 | |
| SCHEMBL6925828 | 0.90 | VEGFA (0.51) | SELPVEGFAAKT1LMNATLR2 | |
| SCHEMBL6925831 | 0.90 | VEGFA (0.51) | SELPVEGFAAKT1LMNATLR2 | |
| SCHEMBL8998274 | 0.90 | SELP (0.51) | SELPVEGFAALDH1A1LMNATLR2 | |
| SCHEMBL13224963 | 0.89 | SELP (0.53) | SELPVEGFAAKT1TLR2 | |
| SCHEMBL3402008 | 0.89 | SELP (0.53) | SELPVEGFAAKT1TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6670361-B2 | Anticancer agents | TOYO SUISAN KAISHA, LTD. (JP) | 2003-12-30 | — | — | US | disclosed |
| US-6518248-B1 | Method of treating gastric or colon cancer by administration of a sulfoquinovosylacylglycerol ester | TOYO SUISAN KAISHA, LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| US-20020173471-A1 | Method of treating cancer | TOYO SUISAN KAISHA, LTD. (JP) | 2002-11-21 | — | — | US | disclosed |
| US-6444795-B1 | ANTICANCER AGENTS | TOYO SUISAN KAISHA, LTD. (JP) | 2002-09-03 | — | — | US | disclosed |
| US-6395886-B1 | ANTICANCER AGENTS | TOYO SUISAN KAISHA, LTD. (JP) | 2002-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173471-A1 | Method of treating cancer | CPT1A, FASN, FADS1 | SELP 4271/4885VEGFA 2750/4885AKT1 1153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.